Rapid and sustained response to JAK inhibition in a child with severe MDA5 + juvenile dermatomyositis.

While there is growing evidence that JAK inhibition is a promising therapeutic option in jDM our case report shows that this approach may also be effective in MDA5-positive jDM with high risk features.